ClinVar Miner

Submissions for variant NM_000136.3(FANCC):c.1065C>A (p.Asp355Glu)

dbSNP: rs1588070592
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Mendelics RCV000988208 SCV001137845 uncertain significance Fanconi anemia complementation group A 2019-05-28 criteria provided, single submitter clinical testing
Cancer Genomics Group, Japanese Foundation For Cancer Research RCV001030699 SCV001193575 likely benign Hereditary breast ovarian cancer syndrome 2019-05-01 criteria provided, single submitter research
Labcorp Genetics (formerly Invitae), Labcorp RCV001064625 SCV001229535 uncertain significance Fanconi anemia 2021-09-02 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid with glutamic acid at codon 355 of the FANCC protein (p.Asp355Glu). The aspartic acid residue is weakly conserved and there is a small physicochemical difference between aspartic acid and glutamic acid. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with FANCC-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV003160115 SCV003859378 uncertain significance Hereditary cancer-predisposing syndrome 2022-11-07 criteria provided, single submitter clinical testing The p.D355E variant (also known as c.1065C>A), located in coding exon 10 of the FANCC gene, results from a C to A substitution at nucleotide position 1065. The aspartic acid at codon 355 is replaced by glutamic acid, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Natera, Inc. RCV001064625 SCV002081186 uncertain significance Fanconi anemia 2019-02-04 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.